Loading...
XSHE
000538
Market cap13bUSD
Mar 31, Last price  
56.80CNY
1D
0.80%
1Q
-5.25%
Jan 2017
-25.41%
Name

Yunnan Baiyao Group Co Ltd

Chart & Performance

D1W1MN
P/E
24.55
P/S
2.57
EPS
2.31
Div Yield, %
3.66%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
7.93%
Revenues
39.11b
+7.19%
1,832,312,1962,448,395,0213,200,335,5134,115,716,8995,723,198,6677,171,784,04310,075,437,83411,312,322,43213,686,824,52515,814,790,88018,814,366,37220,738,126,20522,410,654,40424,314,614,04426,708,213,48729,664,673,86832,742,766,76336,373,919,01636,488,372,64939,111,292,156
Net income
4.09b
+36.41%
171,348,717230,370,274276,395,341336,790,481465,420,155603,719,565926,168,5801,210,908,6661,582,515,8432,321,453,7872,506,076,5012,770,841,4012,919,876,8123,144,981,4293,306,564,3174,183,727,5535,516,072,1782,804,916,7153,001,125,8874,093,782,074
CFO
3.50b
+9.14%
169,346,918286,277,104292,162,70060,503,123806,896,878460,548,807432,083,8840794,948,911341,641,5861,586,864,1792,179,500,4012,984,757,6821,155,689,9482,629,807,2362,104,744,8253,828,906,6325,223,278,2823,209,410,0323,502,742,339
Dividend
May 10, 20242.077 CNY/sh
Earnings
Apr 25, 2025

Profile

Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China and internationally. It provides health products, drugs, medical instruments, Chinese medicine resources, and tea. The company offers its products under the Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong brand names. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.
URL
http://www.yunnanbaiyao.com.cn
IPO date
Dec 15, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
39,111,292
7.19%
36,488,373
0.31%
Cost of revenue
32,365,493
31,642,188
Unusual Expense (Income)
NOPBT
6,745,799
4,846,185
NOPBT Margin
17.25%
13.28%
Operating Taxes
695,451
536,593
Tax Rate
10.31%
11.07%
NOPAT
6,050,349
4,309,592
Net income
4,093,782
36.41%
3,001,126
7.00%
Dividends
(2,747,626)
Dividend yield
3.13%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,747,304
1,944,739
Long-term debt
346,795
573,667
Deferred revenue
238,811
178,622
Other long-term liabilities
653,123
671,003
Net debt
(26,912,618)
(22,308,989)
Cash flow
Cash from operating activities
3,502,742
3,209,410
CAPEX
(575,507)
Cash from investing activities
518,581
Cash from financing activities
(2,920,712)
FCF
5,544,859
6,892,488
Balance
Cash
17,029,532
15,471,836
Long term investments
11,977,185
9,355,559
Excess cash
27,051,152
23,002,976
Stockholders' equity
22,437,773
21,055,761
Invested Capital
20,281,273
20,044,197
ROIC
30.01%
21.28%
ROCE
15.76%
11.76%
EV
Common stock shares outstanding
1,787,678
1,579,540
Price
49.15
-9.58%
54.36
-48.06%
Market cap
87,864,362
2.33%
85,863,793
-54.45%
EV
60,977,982
63,578,128
EBITDA
7,118,996
5,299,794
EV/EBITDA
8.57
12.00
Interest
58,589
67,850
Interest/NOPBT
0.87%
1.40%